Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Interleukin-6 and chronic inflammation.

Cem Gabay1

  • 1Division of Rheumatology, University Hospital of Geneva, Switzerland. cem.gabay@hcuge.ch

Arthritis Research & Therapy
|August 11, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Development and validation of clinical criteria for the definition of disease activity in adult-onset Still's disease: a cohort study.

The Lancet. Rheumatology·2026
Same author

IL1R2 Deficiency Unleashes Neutrophil-Mediated Antitumor Potential in Sarcoma.

Cancer immunology research·2026
Same author

[Rheumatoid arthritis pathogenesis. From susceptibility to autoimmunity, and arthritis].

Revue medicale suisse·2026
Same author

Pyrin inflammasome activation triggers an IL-18-driven IFN-γ response in mevalonate kinase deficiency.

The Journal of allergy and clinical immunology·2026
Same author

A Multifaceted Interplay Among Hemophagocytosis, Interleukin-18, and Type I Interferon Distinguishes Still Disease From Other Autoinflammatory Diseases.

Arthritis & rheumatology (Hoboken, N.J.)·2026
Same author

Cancer cell-intrinsic inflammasome protein ASC links innate immunity with mitochondrial metabolism in driving pancreatic cancer.

Nature communications·2026
Same journal

Differential gene expression of retrotransposons (LTR and non-LTR) in peripheral blood leukocytes of people with gout.

Arthritis research & therapy·2026
Same journal

Alterations in systemic and skeletal muscle myostatin regulation are most prominent at disease onset and associate with muscle-related outcomes in idiopathic inflammatory myopathies.

Arthritis research & therapy·2026
Same journal

Plasma proteome differences between giant cell arteritis and polymyalgia rheumatica: a pilot study.

Arthritis research & therapy·2026
Same journal

Elucidating the mechanism of taurine in alleviating osteoarthritis progression based on bioinformatics, machine learning algorithm, and experimental validation.

Arthritis research & therapy·2026
Same journal

Discovery of biomarkers for primary Sj ögren's syndrome based on multi-omics data, construction of diagnostic models, and clinical correlation analysis.

Arthritis research & therapy·2026
Same journal

Identification of distinct subgroups in Chinese patients with Behçet's syndrome via cluster analysis of immune cells and clinical features.

Arthritis research & therapy·2026
See all related articles

Interleukin-6 (IL-6) drives inflammation and the acute phase response. Targeting IL-6 signaling effectively treats chronic inflammatory diseases like rheumatoid arthritis.

Area of Science:

  • Immunology
  • Inflammation Biology
  • Molecular Medicine

Background:

  • Interleukin-6 (IL-6) is a key cytokine produced at inflammatory sites.
  • IL-6 mediates the acute phase response, including acute phase protein production.
  • IL-6 signaling is crucial for transitioning inflammation from acute to chronic phases.

Purpose of the Study:

  • To elucidate the role of IL-6 and its soluble receptor (sIL-6Ralpha) in inflammation.
  • To investigate the impact of IL-6 on leukocyte infiltration and immune cell activation.
  • To evaluate the therapeutic potential of targeting IL-6 signaling in chronic inflammatory diseases.

Main Methods:

  • Analysis of IL-6 production at inflammatory sites.
  • Assessment of leukocyte infiltrate changes (neutrophils to macrophages).

Related Experiment Videos

  • Evaluation of IL-6 effects on T-cell and B-cell activation.
  • Testing of IL-6 targeting strategies in preclinical models of chronic inflammation.

    • Main Results:

    • IL-6 influences the shift in leukocyte populations during inflammation.
    • IL-6 promotes T-cell and B-cell stimulation, contributing to chronicity.
    • Targeting IL-6 and its signaling pathways demonstrated efficacy.
    • Successful prevention and treatment observed in models of rheumatoid arthritis and other chronic inflammatory conditions.

    Conclusions:

    • IL-6 plays a pivotal role in both acute and chronic inflammatory processes.
    • The IL-6/sIL-6Ralpha pathway is critical for modulating inflammatory cell infiltration and immune cell responses.
    • Targeting IL-6 represents a promising therapeutic strategy for managing chronic inflammatory diseases.